Platelet Signaling
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
This chapter summarizes current ideas about the intracellular signaling that drives platelet responses to vascular injury. After a brief overview of platelet activation intended to place the signaling pathways into context, the first section considers the early events of platelet activation leading up to integrin activation and platelet aggregation. The focus is on the G protein-mediated events utilized by agonists such as thrombin and ADP, and the tyrosine kinase-based signaling triggered by collagen. The second section considers the events that occur after integrin engagement, some of which are dependent on close physical contact between platelets. A third section addresses the regulatory events that help to avoid unprovoked or excessive platelet activation, after which the final section briefly considers individual variations in platelet reactivity and the role of platelet signaling in the innate immune response and embryonic development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The final steps of integrin activation: the end game
Shattil, S. J., Kim, C., & Ginsberg, M. H. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2871 · Cited by 1,086 · cited 2×
“This leads to integrin activation via a pathway that currently includes a Ca2+-dependent exchange factor (CalDAG-GEF), a switch (Rap1), an adaptor (RIAM), and proteins that interact directly with the integrin cytosolic domains (kindlin and talin) (Shattil et al. 2010).”
BackgroundAltered pain perception and inflammatory response in mice lacking prostacyclin receptor
Murata, T., Ushikubi, F., Matsuoka, T., Hirata, M., Yamasaki, A., Sugimoto, Y., Ichikawa, A., Aze, Y., Tanaka, T., Yoshida, N., et al. (1997) · Nature · doi:10.1038/41780 · Cited by 773 · cited 2×
“Conversely, loss of PGI2 receptor (IP) expression causes a decrease in basal cAMP levels, enhances responses to agonists and predisposes mice to thrombosis in arterial injury models (Murata et al. 1997; Yang et al. 2002).”
BackgroundRGS-containing RhoGEFs: the missing link between transforming G proteins and Rho?
Fukuhara, S., Chikumi, H., & Gutkind, J. S. (2001) · Oncogene · doi:10.1038/sj.onc.1204182 · Cited by 219 · cited 2×
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript family members to Rho family members, including p115RhoGEF (Fukuhara et al. 2001).”
Background
Cited by
Platelets and cancer: a casual or causal relationship: revisited
Menter, D. G., Tucker, S. C., Kopetz, S., Sood, A. K., Crissman, J. D., & Honn, K. V. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-014-9498-0 · Cited by 316
Atherosclerosis and Inflammation: Insights from the Theory of General Pathological Processes
Gusev, E., & Sarapultsev, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097910 · Cited by 312
Platelet Signaling and Disease: Targeted Therapy for Thrombosis and Other Related Diseases
Yeung, J., Li, W., & Holinstat, M. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014530 · Cited by 242
“Gaq transmits its signal primarily through the activation of phospholipase C (PLC)b, which subsequently induces second messenger signaling through formation of IP3 and DAG (Hung et al., 1992; Offermanns et al., 1997; Holinstat et al., 2009; Stalker et al., 2012; Edelstein et al., 2014).”
BackgroundInfluential
Metadata
- Authors
- Stalker, T. J., Newman, D. K., Ma, P., Wannemacher, K. M., & Brass, L. F.
- Venue
- Handbook of Experimental Pharmacology
- Publisher
- Springer Berlin Heidelberg
- Published
- 2012
- Issue
- 210
- Pages
- 59-85
- ISSN
- 0171-2004 (ISSN-L)
- 1865-0325
- OpenAlex
- W4251470689
- Cited by
- 167
- References
- 3
- FWCI
- 19.16
- Type
- book chapter
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.